(LifeSiteNews) — The U.S. Food & Drug Administration (FDA) has notified pharmaceutical giant Moderna that it will not be reviewing its application for a new mRNA-based flu vaccine, continuing the Trump administration’s pivot away from the technology that was introduced to the country with the controversial COVID-19 shots.
Time magazine reports that almost two years ago, Moderna submitted Phase 3 data touting the purported effectiveness of mRNA 1010.6, the first influenza vaccine to use mRNA, and has been in talks with the government ever since. But on February 3, it received a Refusal to File letter from the FDA declaring its application “is not sufficiently complete to enable a substantive review.”
